Hengrui Medicine gets green light for HRS-6213 trial

Jiangsu Hengrui Medicine (SSE:600276) announced that its subsidiary, Tianjin Hengrui Pharmaceutical, has received clinical trial approval from the National Medical Products Administration for HRS-6213 injection. The drug, indicated for PET imaging in solid tumor diagnosis and assessment, will proceed to clinical trials. HRS-6213 works by binding to tumor proteins, emitting positrons, and generating high-resolution tomographic images. Currently, no similar products have been approved domestically or internationally. The company has invested approximately 8.93 million yuan in the HRS-6213 project to date. Hengrui Medicine cautioned that the drug's development is subject to uncertainties and regulatory approvals, and urged investors to exercise caution.